Potential clinical benefits of quercetin in the early stage of COVID-19: results of a second, pilot, randomized, controlled and open-label clinical trial
F Di Pierro, S Iqtadar, A Khan… - … journal of general …, 2021 - Taylor & Francis
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
[HTML][HTML] Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
F Di Pierro, S Iqtadar, A Khan, SU Mumtaz… - … Journal of General …, 2021 - ncbi.nlm.nih.gov
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial.
F Di Pierro, S Iqtadar, A Khan, M Chaudhry… - … Journal of General …, 2021 - europepmc.org
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
[PDF][PDF] Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
F Di Pierro, S Iqtadar, A Khan… - … Journal of General …, 2021 - pdfs.semanticscholar.org
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
F Di Pierro, S Iqtadar, A Khan… - … journal of general …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
F Di Pierro, S Iqtadar, A Khan, S Mumtaz… - INTERNATIONAL …, 2021 - iris.unipv.it
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
[PDF][PDF] Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
F Di Pierro, S Iqtadar, A Khan, SU Mumtaz… - International Journal of …, 2021 - mednews.care
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial.
F Di Pierro, S Iqtadar, A Khan, SU Mumtaz… - International Journal of …, 2021 - go.gale.com
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
[PDF][PDF] Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
F Di Pierro, S Iqtadar, A Khan, SU Mumtaz… - International Journal of …, 2021 - academia.edu
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
[PDF][PDF] Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
F Di Pierro, S Iqtadar, A Khan, SU Mumtaz… - … Journal of General …, 2021 - researchgate.net
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …